Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.85 |
| ▸ | EPHA2 | P29317 | 5/20 | 0.85 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.85 |
| ▸ | FLT1 | P17948 | 1/20 | 0.85 |
| ▸ | EGFR | P00533 | 13/20 | 0.73 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.73 |
| ▸ | FBP1 | P09467 | 2/20 | 0.73 |
| ▸ | AURKA | O14965 | 1/20 | 0.73 |
| ▸ | INSR | P06213 | 1/20 | 0.73 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.73 |
| ▸ | FLT4 | P35916 | 1/20 | 0.73 |
| ▸ | CLK1 | P49759 | 1/20 | 0.73 |
| ▸ | TEK | Q02763 | 1/20 | 0.73 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.73 |
| ▸ | RET | P07949 | 1/20 | 0.68 |
| ▸ | KIF5B | P33176 | 1/20 | 0.68 |
| ▸ | GAK | O14976 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL906880 | 0.92 | EPHA2 (1.00) | KDREPHA2EPHB4FLT1EGFR | |
| SCHEMBL17557985 | 0.90 | EGFR (0.80) | KDREPHA2EPHB4EGFRERBB2 | |
| SCHEMBL17520378 | 0.90 | EGFR (0.80) | KDREPHA2EPHB4EGFRERBB2 | |
| SCHEMBL7859585 | 0.86 | FLT1 (0.80) | KDREPHA2EPHB4FLT1EGFR | |
| SCHEMBL30505605 | 0.86 | EGFR (1.00) | KDREPHB4EGFRERBB2FBP1 | |
| SCHEMBL2099106 | 0.86 | EGFR (1.00) | KDREPHB4EGFRERBB2FBP1 | |
| Hydrochloric Acid SCHEMBL7710205 | 0.85 | FLT1 (0.79) | KDREPHA2EPHB4FLT1EGFR | |
| Hydrochloric Acid SCHEMBL27887194 | 0.84 | EGFR (0.98) | KDREPHB4EGFRERBB2FBP1 | |
| SCHEMBL6187027 | 0.84 | EGFR (0.77) | KDREPHA2EPHB4EGFRERBB2 | |
| SCHEMBL8307447 | 0.84 | KDR (0.76) | KDREPHA2EPHB4FLT1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030018029-A1 | Quinazoline derivatives | ZENECA LIMITED | 2003-01-23 | — | — | US | claimed |
| US-6399602-B1 | ANTICANCER AGENTS | ZENECA LIMITED (GB) | 2002-06-04 | — | — | US | claimed |
| EP-0880507-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | claimed |
| WO-1997030034-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | claimed |
| US-6897214-B2 | Quinazoline derivatives | ZENECA LIMITED (GB) | 2005-05-24 | — | — | US | disclosed |
| EP-0880507-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| US-20030018029-A1 | Quinazoline derivatives | ZENECA LIMITED | 2003-01-23 | — | — | US | disclosed |
| US-6399602-B1 | ANTICANCER AGENTS | ZENECA LIMITED (GB) | 2002-06-04 | — | — | US | disclosed |
| US-5866572-A | RECEPTOR TYROSINE KINASE INHIBITORY PROPERTIES, TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER. | ZENECA LIMITED (GB) | 1999-02-02 | — | — | US | disclosed |
| EP-0880507-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997030034-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018029-A1 | Quinazoline derivatives | ABL1, FGFR1, ERBB2 | KDR 309/4885EPHA2 1053/4885EPHB4 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.